Merck
Trade Merck 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
Stock Snapshot
With a market cap of 242.77B, Merck(MRK) trades at $98.10. The stock has a price-to-earnings ratio of 12.56 and currently yields dividends of 3.4%.
As of 2025-11-21, Merck(MRK) stock has fluctuated between $95.08 and $100.27. The current price stands at $98.10, placing the stock +3.2% above today's low and -2.2% off the high.
The Merck(MRK)'s current trading volume is 23.15M, compared to an average daily volume of 15.16M.
During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.07 at its peak.
During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.07 at its peak.
MRK News
Merck (MRK) announced that the U.S. FDA has approved Keytruda and Keytruda Qlex in combination with Padcev as neoadjuvant treatment and then continued after cys...
Shares of Merck & Company, Inc. (NASDAQ:MRK) are trading higher the FDA approved pembrolizumab with enfortumab vedotin-ejfv for muscle-invasive bladder cancer....
The pharmaceutical giant's post-Keytruda plans continue to take shape. Over the past two years, Merck (MRK +0.06%) has faced several challenges, resulting in a...
Analyst ratings
59%
of 29 ratingsMore MRK News
Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen...
Merck (MRK) announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, single-tablet regimen of d...
Merck (MRK) announced that the European Commission has approved a new subcutaneous, or under the skin, route of administration and a new pharmaceutical form of...
In November 2025, Merck announced a quarterly dividend increase and released positive clinical trial results for both WINREVAIR in pulmonary hypertension and en...
Merck & Co. Inc. (NYSE:MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and...
In a report released yesterday, Tim Anderson from Bank of America Securities reiterated a Buy rating on Merck & Company, with a price target of $105.00. Meet Yo...
BofA analyst Tim Anderson raised the firm’s price target on Merck (MRK) to $105 from $98 and keeps a Buy rating on the shares. The Cidara (CDTX) deal is a “reas...